mRNA & Future Vaccines

A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived dramatically longer than those who didn’t. Researchers from the University of Florida and MD Anderson Cancer Center discovered that the vaccine’s immune-activating properties may boost cancer-fighting responses, acting like a nonspecific “flare” that reawakens the immune system.

COVID-19 mRNA vaccines induce robust humoral immune responses with differences in epitope recognition and antibody-mediated functional properties.

Tailoring Immunization Strategies to Protect Those Who Need It Most

An experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacteria that causes Lyme disease. Results suggest that the vaccine prevents the development of Lyme disease.

Cancer vaccines have gained much interest among scientists but face a number of hurdles. A new mRNA vaccine for glioma offers a step forward in training the immune system to fight cancer.

Dalan Animal Health is working to sell its bee vaccines to commercial beekeepers and governments – and potentially expand to other invertebrates.

There’s still a long way to go, but RNA vaccines might help in the fight against malaria.

Interim Com-COV2 trial data evaluated two-dose COVID-19 vaccination regimens with first dose of BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) alongside second dose as either homologous vaccination, heterologous NVX-CoV2373 (Novavax) vaccination, or heterologous mRNA-1273 (Moderna) vaccination.1 These data showed that ChAdOx1 nCoV-19 vaccination followed by NVX-CoV2373 vaccination drove optimal T-cell immunogenicity and excellent antibody induction. These heterologous vaccine approach findings are now likely to be extrapolated in developing scheduling strategies for other vaccines.

Beijing approves the first vaccine of its kind as it looks to jumpstart its flailing economy

Having access to an mRNA vaccine will be critical to China’s ongoing COVID response.

China's labs have spent years trying to create an mRNA vaccine - its own shots were less effective.

Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path ahead to catch up to…

Researchers from the California Institute of Technology say the “mosaic-8” vaccine could protect people from other coronaviruses, including SARS and MERS.

Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals. The